Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT06307431
Title A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme LLC
Age Groups: senior | adult
Covered Countries USA | CAN | AUS

No variant requirements are available.